融资需求：7000万。出让股权：30%。

Our biotech company is dedicated to developing innovative treatments for oncology patients, focused on best-in-class or first-in-class small molecular drug discovery and development. We believe that by leveraging cutting-edge technologies and a deep understanding of oncology biology, we can make a significant impact on the lives of patients and generate significant value for our investors. Our experienced team consists of biologists, chemists, and entrepreneurs who are dedicated to advancing oncology treatment options.

更多完整项目资料在商业计划书中，欢迎了解后约谈。